In re Effexor XR Direct Purchaser Antitrust Litigation (D.N.J.)

As a member of the Executive Committee, we represent direct purchasers of Effexor XR who were prevented from substituting less expensive generic versions of Effexor XR because of Defendants’ alleged scheme to monopolize the market, that included committing fraud to secure a patent and making a large payment to a generic competitor to delay the generic from entering the market. The district court denied Defendants’ motion to dismiss the patent fraud claim but dismissed the reverse payment claim, which was reversed on appeal. Discovery is ongoing on all claims

Scroll to Top